With Traditional Chinese Medicine Deal, Nestle’s Health Science Business Reaches Into Pharma Development
This article was originally published in The Pink Sheet Daily
Executive Summary
A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&D firm’s long search for a partner.
You may also be interested in...
Nestlé Gets Serious With Seres Deal
The January Nestlé Health-Seres alliance nets Seres one of the biggest up-front payments in several years for an ex-US product license, while Nestlé shows its continuing commitment to building a portfolio of GI nutritional therapeutics – an area where development efforts have been slow to take shape.
Nestlé Health Science Plans Continuum Of Care
Nestlé’s announcement on May 24 that its new health sciences subsidiary is buying Prometheus Laboratories, a gastrointestinal drug and diagnostic company, takes the food company in a new direction, but also raises questions for pharma.
Nestle Gains GI Diagnostics For Nutritional Health Biz Via Prometheus Deal
Nestle Health Science will add gastrointestinal diagnostic services to its nutritional health business by acquiring Prometheus Laboratories for undisclosed terms in a deal announced May 24.